JP2018524327A - チロシンキナーゼ阻害剤の眼科用製剤、その医薬組成物およびその調製方法 - Google Patents
チロシンキナーゼ阻害剤の眼科用製剤、その医薬組成物およびその調製方法 Download PDFInfo
- Publication number
- JP2018524327A JP2018524327A JP2017566347A JP2017566347A JP2018524327A JP 2018524327 A JP2018524327 A JP 2018524327A JP 2017566347 A JP2017566347 A JP 2017566347A JP 2017566347 A JP2017566347 A JP 2017566347A JP 2018524327 A JP2018524327 A JP 2018524327A
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic
- pharmaceutically acceptable
- nintedanib
- tyrosine kinase
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 145
- 238000009472 formulation Methods 0.000 title claims abstract description 120
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims abstract description 59
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims abstract description 59
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims abstract description 79
- 229960004378 nintedanib Drugs 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 68
- 239000002105 nanoparticle Substances 0.000 claims abstract description 48
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims abstract description 46
- 229960003005 axitinib Drugs 0.000 claims abstract description 46
- 201000002154 Pterygium Diseases 0.000 claims abstract description 40
- 239000011859 microparticle Substances 0.000 claims abstract description 28
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 206010020565 Hyperaemia Diseases 0.000 claims abstract description 20
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims abstract description 20
- 229960003787 sorafenib Drugs 0.000 claims abstract description 20
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims abstract description 16
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960000639 pazopanib Drugs 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims description 44
- 239000000651 prodrug Substances 0.000 claims description 43
- 229940002612 prodrug Drugs 0.000 claims description 43
- 201000000159 corneal neovascularization Diseases 0.000 claims description 41
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 40
- 208000023715 Ocular surface disease Diseases 0.000 claims description 29
- 239000006194 liquid suspension Substances 0.000 claims description 25
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 24
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 23
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 23
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 23
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- 229920001664 tyloxapol Polymers 0.000 claims description 18
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 18
- 229960004224 tyloxapol Drugs 0.000 claims description 18
- 210000000795 conjunctiva Anatomy 0.000 claims description 16
- 230000000699 topical effect Effects 0.000 claims description 16
- 230000033115 angiogenesis Effects 0.000 claims description 15
- -1 polyoxyethylene Polymers 0.000 claims description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 14
- 229920002674 hyaluronan Polymers 0.000 claims description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims description 14
- 230000003204 osmotic effect Effects 0.000 claims description 11
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 7
- 229950005134 polycarbophil Drugs 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 229960001631 carbomer Drugs 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 5
- 206010021143 Hypoxia Diseases 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 5
- 206010010705 conjunctival degeneration Diseases 0.000 claims description 5
- 208000008025 hordeolum Diseases 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 206010023332 keratitis Diseases 0.000 claims description 5
- 201000008106 ocular cancer Diseases 0.000 claims description 5
- 208000003154 papilloma Diseases 0.000 claims description 5
- 229940021506 stye Drugs 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 208000024519 eye neoplasm Diseases 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 206010038886 Retinal oedema Diseases 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 abstract description 8
- 239000002245 particle Substances 0.000 description 115
- 210000001508 eye Anatomy 0.000 description 57
- 239000000725 suspension Substances 0.000 description 40
- 238000000227 grinding Methods 0.000 description 25
- 239000006070 nanosuspension Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000003902 lesion Effects 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 17
- 239000003085 diluting agent Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 210000004087 cornea Anatomy 0.000 description 16
- 238000009826 distribution Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000000227 bioadhesive Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 11
- 229940100654 ophthalmic suspension Drugs 0.000 description 11
- 229940120638 avastin Drugs 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000011200 topical administration Methods 0.000 description 8
- 206010029113 Neovascularisation Diseases 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 7
- 238000000265 homogenisation Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000011587 new zealand white rabbit Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229920001993 poloxamer 188 Polymers 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 5
- 229960000487 sorafenib tosylate Drugs 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940023490 ophthalmic product Drugs 0.000 description 4
- 238000007415 particle size distribution analysis Methods 0.000 description 4
- 229940044519 poloxamer 188 Drugs 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091008794 FGF receptors Proteins 0.000 description 3
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 238000000498 ball milling Methods 0.000 description 3
- 238000011095 buffer preparation Methods 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000010951 particle size reduction Methods 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 229940044476 poloxamer 407 Drugs 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 239000008181 tonicity modifier Substances 0.000 description 3
- 238000001238 wet grinding Methods 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000024304 Choroidal Effusions Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009837 dry grinding Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910001928 zirconium oxide Inorganic materials 0.000 description 2
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- UEIZUEWXLJOVLD-UHFFFAOYSA-N 3-(1-methylpyrrolidin-3-yl)pyridine Chemical compound C1N(C)CCC1C1=CC=CN=C1 UEIZUEWXLJOVLD-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940073464 benzododecinium bromide Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000027129 choroid disease Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 206010015915 eye discharge Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000000593 microemulsion method Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 230000009972 noncorrosive effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- XVNVFKZODWAQKN-UHFFFAOYSA-N phosphoric acid;heptahydrate Chemical compound O.O.O.O.O.O.O.OP(O)(O)=O XVNVFKZODWAQKN-UHFFFAOYSA-N 0.000 description 1
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000002398 sedimentation field-flow fractionation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 229940032912 zephiran Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本願は、その開示が参照により本願に組み込まれている、2015年6月22日に出願された米国仮出願番号62/183,180号に基づき、米国特許法119条(e)による優先権を主張する。
本発明は、ニンテダニブ、アキシチニブおよびソラフェニブなどのチロシンキナーゼ阻害剤を含む眼科用製剤、および眼表面疾患の治療のためのそのような眼科用製剤の使用に関する。
実施形態1は、治療有効量のニンテダニブ、そのプロドラッグ、またはその薬学的に許容される塩、および少なくとも1つの薬学的に許容される賦形剤を含む眼科用製剤である。
(a)約0.1%w/v〜約10%w/vの濃度のニンテダニブまたはその薬学的に許容される塩を含む治療有効量のナノ粒子;
(b)約0.01%〜0.3%のチロキサポール;および
(c)約0.1%〜1%のHPMC
を含み、製剤が局所投与のための液体懸濁剤である眼科用製剤である。
200mLのHPMCの調製のために、以下の手順に従った。
(1)水(150mL)を約80℃に加熱した(連続攪拌下)。
(2)HPMC(4g)を徐々に水に添加して(一定撹拌下)、HPMC溶液を形成した。
(3)HPMC溶液をよく分散させて、懸濁させるまで混合した。
(4)HPMC溶液を200mLのメスフラスコに定量的に移し、精製水をほぼ最終体積まで加えた。
(5)メスフラスコを絶え間なく攪拌しながら水浴に置き、室温まで冷却し、そして
(6)精製水を加えて最終容量200mLとし、よく混合した。
200mLの5×緩衝液の調製のために、以下の手順に従った。
(1)リン酸二水素七水和物(2.7mg)、リン酸一水素一水和物(0.3g)、塩化ナトリウム(8.5g)、エデト酸二ナトリウム(1.0g)、ポリソルベート80(1.0g)および塩化ベンザルコニウム(0.050g)を180mLの精製水に溶解した。
(2)1N NaOHでpHを7.4に調整した。
(3)緩衝液を200mLのメスフラスコに移し、そして
(4)精製水を加えて最終容量200mLとし、緩衝液をよく混合した。
(1)ニンテダニブエタンスルホネート(45.37mg)およびビヒクル(14.97515g)を20mLのシンチレーションバイアルに秤量し、撹拌棒を加え、バイアルにしっかりと蓋をした。
(2)バイアルを約1分間、超音波処理で回転させた。
(3)バイアルを約30秒間振とうして、大きなAPI凝集体を分散させた。
(4)バイアルを約1分間超音波処理で回転させた。
(5)バイアルを磁気攪拌プレート上で高速で5分間混合した。
(6)ニンテダニブエタンスルホネートが均一に分散/懸濁し、目に見える凝集物が残らなくなるまで、必要に応じて(3)〜(5)の手順を繰り返した(総混合および超音波処理時間は約1.25時間と推定された)。
(7)バイアルをマグネチックスターラー上でさらに10分間混合して、0.3%のニンテダニブエタンスルホネートを含む眼科用液体懸濁液を得た。
(1)アキシチニブ(150.24mg)およびビヒクル(14.8225g)を20mLのシンチレーションバイアルに秤量し、撹拌棒を加え、バイアルにしっかりと蓋をした。
(2)バイアルを約2分間超音波処理して回転させた。
(3)バイアルを振盪してアキシチニブの大きな凝集体を約30秒間分散させた。
(4)バイアルを超音波処理し、断続的に1分間回転させた。
(5)バイアルを磁気攪拌プレート上で高速で5分間混合した。
(6)アキシチニブが均一に分散/懸濁し、目に見える凝集物が残らなくなるまで、必要に応じて(3)〜(5)の手順を繰り返した(総混合および超音波処理時間は約0.5時間と推定される)。
(7)バイアルをマグネチックスターラー上でさらに10分間混合して、1%アキシチニブを含有する眼科用液体懸濁液を得た。
(付記1)
治療有効量のニンテダニブ、そのプロドラッグまたはその薬学的に許容される塩、および少なくとも1つの薬学的に許容される賦形剤を含む眼科用製剤。
前記少なくとも1つの薬学的に許容される賦形剤は、界面活性剤、防腐剤、粘度調整剤、pH調整剤、安定化剤および浸透圧調整剤からなる群から選択される、
ことを特徴とする付記1に記載の眼科用製剤。
前記界面活性剤は、Tween80、Tween20、ポリソルベート、ポロキサマーおよびチロキサポールからなる群から選択される、
ことを特徴とする付記2に記載の眼科用製剤。
前記界面活性剤は、チロキサポールである、
ことを特徴とする付記3に記載の眼科用製剤。
前記粘度調節剤は、ヒドロキシプロピルメチルセルロース(HPMC)、カルボキシメチルセルロースナトリウム、カルボマー、ポリカルボフィル、ポリオキシエチレングリコール(PEG)およびヒアルロン酸(HA)からなる群から選択される、
ことを特徴とする付記2に記載の眼科用製剤。
前記眼科用製剤は、ニンテダニブ、そのプロドラッグまたはその薬学的に許容される塩を含む微粒子またはナノ粒子を含む、
ことを特徴とする付記1乃至5のいずれか1項に記載の眼科用製剤。
前記製剤は、局所眼投与のための液体懸濁液である、
ことを特徴とする付記1乃至6のいずれか1項に記載の眼科用製剤。
ニンテダニブ、そのプロドラッグまたはその薬学的に許容される塩の濃度は、0.01%〜10%w/vである、
ことを特徴とする付記1乃至7のいずれか1項に記載の眼科用製剤。
アキシチニブ、ニンテダニブ、ソラフェニブ、パゾパニブ、それらのプロドラッグおよびそれらの薬学的に許容される塩からなる群から選択されるチロシンキナーゼ阻害剤を含む治療有効量のナノ粒子ならびに少なくとも1つの薬学的に許容される賦形剤を含む眼科用製剤。
前記チロシンキナーゼ阻害剤の濃度は、0.01%〜10%w/vである、
ことを特徴とする付記9に記載の眼科用製剤。
前記製剤は、局所眼投与のための液体懸濁液である、
ことを特徴とする付記9または10に記載の眼科用製剤。
付記1乃至11のいずれか1項に記載の眼科用製剤を対象の眼に投与することを含む、必要とする対象における眼表面疾患を治療する方法。
前記眼表面疾患は、眼の前部における血管新生、角膜炎、角膜移植または角膜形成術後の角膜血管新生、遅い増殖を伴う結膜変性(結膜)、結膜乳頭腫、低酸素による角膜血管新生、充血、翼状片に関連する充血、甲状腺機能亢進症による眼の鬱血、ドライアイ、網膜内浮腫、黄斑浮腫、網膜静脈閉塞による黄斑浮腫、新血管新生緑内障(NVG)、眼の癌、翼状結膜炎、再発性翼状片、スティーブンジョンソン症候群、麦粒腫および網膜下浮腫からなる群から選択される、
ことを特徴とする付記12に記載の方法。
前記眼表面疾患は、翼状片に関連する充血、翼状結膜炎、再発性翼状片または角膜血管新生である、
ことを特徴とする付記13に記載の方法。
アキシチニブ、ニンテダニブ、ソラフェニブ、パゾパニブ、それらのプロドラッグおよびそれらの薬学的に許容される塩からなる群から選択されるチロシンキナーゼ阻害剤のナノ粒子または微粒子を任意に形成することと、チロシンキナーゼ阻害剤またはその微粒子もしくはナノ粒子を少なくとも1つの薬学的に許容される賦形剤と組み合わせることと、を含む付記1乃至11のいずれか1項に記載の眼科用製剤の調製方法。
Claims (15)
- 治療有効量のニンテダニブ、そのプロドラッグまたはその薬学的に許容される塩、および少なくとも1つの薬学的に許容される賦形剤を含む眼科用製剤。
- 前記少なくとも1つの薬学的に許容される賦形剤は、界面活性剤、防腐剤、粘度調整剤、pH調整剤、安定化剤および浸透圧調整剤からなる群から選択される、
ことを特徴とする請求項1に記載の眼科用製剤。 - 前記界面活性剤は、Tween80、Tween20、ポリソルベート、ポロキサマーおよびチロキサポールからなる群から選択される、
ことを特徴とする請求項2に記載の眼科用製剤。 - 前記界面活性剤は、チロキサポールである、
ことを特徴とする請求項3に記載の眼科用製剤。 - 前記粘度調節剤は、ヒドロキシプロピルメチルセルロース(HPMC)、カルボキシメチルセルロースナトリウム、カルボマー、ポリカルボフィル、ポリオキシエチレングリコール(PEG)およびヒアルロン酸(HA)からなる群から選択される、
ことを特徴とする請求項2に記載の眼科用製剤。 - 前記眼科用製剤は、ニンテダニブ、そのプロドラッグまたはその薬学的に許容される塩を含む微粒子またはナノ粒子を含む、
ことを特徴とする請求項1乃至5のいずれか1項に記載の眼科用製剤。 - 前記製剤は、局所眼投与のための液体懸濁液である、
ことを特徴とする請求項1乃至6のいずれか1項に記載の眼科用製剤。 - ニンテダニブ、そのプロドラッグまたはその薬学的に許容される塩の濃度は、0.01%〜10%w/vである、
ことを特徴とする請求項1乃至7のいずれか1項に記載の眼科用製剤。 - アキシチニブ、ニンテダニブ、ソラフェニブ、パゾパニブ、それらのプロドラッグおよびそれらの薬学的に許容される塩からなる群から選択されるチロシンキナーゼ阻害剤を含む治療有効量のナノ粒子ならびに少なくとも1つの薬学的に許容される賦形剤を含む眼科用製剤。
- 前記チロシンキナーゼ阻害剤の濃度は、0.01%〜10%w/vである、
ことを特徴とする請求項9に記載の眼科用製剤。 - 前記製剤は、局所眼投与のための液体懸濁液である、
ことを特徴とする請求項9または10に記載の眼科用製剤。 - 請求項1乃至11のいずれか1項に記載の眼科用製剤を対象の眼に投与することを含む、必要とする対象における眼表面疾患を治療する方法。
- 前記眼表面疾患は、眼の前部における血管新生、角膜炎、角膜移植または角膜形成術後の角膜血管新生、遅い増殖を伴う結膜変性(結膜)、結膜乳頭腫、低酸素による角膜血管新生、充血、翼状片に関連する充血、甲状腺機能亢進症による眼の鬱血、ドライアイ、網膜内浮腫、黄斑浮腫、網膜静脈閉塞による黄斑浮腫、新血管新生緑内障(NVG)、眼の癌、翼状結膜炎、再発性翼状片、スティーブンジョンソン症候群、麦粒腫および網膜下浮腫からなる群から選択される、
ことを特徴とする請求項12に記載の方法。 - 前記眼表面疾患は、翼状片に関連する充血、翼状結膜炎、再発性翼状片または角膜血管新生である、
ことを特徴とする請求項13に記載の方法。 - アキシチニブ、ニンテダニブ、ソラフェニブ、パゾパニブ、それらのプロドラッグおよびそれらの薬学的に許容される塩からなる群から選択されるチロシンキナーゼ阻害剤のナノ粒子または微粒子を任意に形成することと、チロシンキナーゼ阻害剤またはその微粒子もしくはナノ粒子を少なくとも1つの薬学的に許容される賦形剤と組み合わせることと、を含む請求項1乃至11のいずれか1項に記載の眼科用製剤の調製方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562183180P | 2015-06-22 | 2015-06-22 | |
US62/183,180 | 2015-06-22 | ||
PCT/US2016/034822 WO2016209555A1 (en) | 2015-06-22 | 2016-05-27 | Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018524327A true JP2018524327A (ja) | 2018-08-30 |
JP6680807B2 JP6680807B2 (ja) | 2020-04-15 |
Family
ID=57586141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017566347A Active JP6680807B2 (ja) | 2015-06-22 | 2016-05-27 | チロシンキナーゼ阻害剤の眼科用製剤、医薬組成物ならびに翼状片およびその症状治療用医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (3) | US10154994B2 (ja) |
EP (1) | EP3310339A4 (ja) |
JP (1) | JP6680807B2 (ja) |
KR (2) | KR102096296B1 (ja) |
CN (1) | CN107708664B (ja) |
AU (1) | AU2016283517B2 (ja) |
CA (1) | CA2989121C (ja) |
MX (1) | MX2017016655A (ja) |
TW (2) | TWI700085B (ja) |
WO (1) | WO2016209555A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019534870A (ja) * | 2016-09-26 | 2019-12-05 | ルヤン (スーチョウ) バイオロジー サイエンス アンド テクノロジー カンパニー,リミテッド | 眼疾患の治療のための組成物ならびに使用および調製方法 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
CN108135737B (zh) | 2015-06-06 | 2021-11-05 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
TWI700085B (zh) | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
CN108295072A (zh) * | 2015-12-09 | 2018-07-20 | 瑞阳(苏州)生物科技有限公司 | 尼达尼布防治眼部疾病的用途 |
JP7079243B2 (ja) | 2016-06-02 | 2022-06-01 | エイディーエス セラピューティクス リミテッド ライアビリティ カンパニー | 緑内障手術の成功率を向上させるためにニンテダニブを使用する組成物および方法 |
US11278546B2 (en) * | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
LT3513809T (lt) | 2016-09-13 | 2022-05-10 | Kyowa Kirin Co., Ltd. | Medicininė kompozicija, apimanti tivozanibą |
WO2018165865A1 (zh) | 2017-03-14 | 2018-09-20 | 新源生物科技股份有限公司 | 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 |
US20200345637A1 (en) * | 2018-01-19 | 2020-11-05 | Aiviva Biopharma, Inc. | Suspension compositions of multi-target inhibitors |
IT201800005599A1 (it) * | 2018-05-22 | 2019-11-22 | Lente a contatto morbida | |
CN112654345A (zh) * | 2018-09-10 | 2021-04-13 | 台湾微脂体股份有限公司 | 缓释眼用药物组合物及其用途 |
CN110664757B (zh) * | 2018-11-19 | 2022-08-02 | 成都瑞沐生物医药科技有限公司 | 纳米晶滴眼剂、其制备方法及其应用 |
CA3134362A1 (en) * | 2019-04-22 | 2020-10-29 | Hampar L. Karageozian | Compositions and methods useable for treatment of dry eye |
WO2020223177A1 (en) * | 2019-04-29 | 2020-11-05 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
CA3146811A1 (en) * | 2019-09-10 | 2021-03-18 | Cloudbreak Therapeutics, Llc | Methods for alleviating pterygium-associated worry about eye appearance |
WO2022003037A1 (en) * | 2020-06-30 | 2022-01-06 | Oculis SA | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery |
EP4351559A1 (en) * | 2021-06-08 | 2024-04-17 | The United States Government As Represented By The Department Of Veterans Affairs | Nanoformulations of pazopanib, compositions comprising the same and methods of treating osteoarthritis |
CA3232086A1 (en) * | 2021-10-15 | 2023-04-20 | Peter Jarrett | Prodrugs of axitinib |
CN116251186A (zh) * | 2021-12-09 | 2023-06-13 | 成都瑞沐生物医药科技有限公司 | 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途 |
WO2023235267A2 (en) * | 2022-05-28 | 2023-12-07 | Avalyn Pharma Inc. | Nintedanib and nintedanib combination dry powder compositions and uses |
KR20240028815A (ko) | 2022-08-25 | 2024-03-05 | 주식회사 스카이테라퓨틱스 | 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물 |
WO2024064848A2 (en) * | 2022-09-23 | 2024-03-28 | Inoculus Ventures, Inc. | Dry eye treatment |
WO2024081410A1 (en) * | 2022-10-14 | 2024-04-18 | Ocular Therapeutix, Inc. | Prodrugs, formulations and methods thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013166436A1 (en) * | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
WO2014074823A1 (en) * | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
JP2018521120A (ja) * | 2015-06-06 | 2018-08-02 | クラウドブレイク・セラピューティクス・エル・エル・シー | 翼状片を治療するための組成物及び方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071904A (en) * | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20080003219A1 (en) | 2005-09-26 | 2008-01-03 | Minu, L.L.C. | Delivery of an ocular agent |
WO2007038453A2 (en) | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
TW200820991A (en) * | 2006-07-10 | 2008-05-16 | Elan Pharma Int Ltd | Nanoparticulate sorafenib formulations |
RU2351298C1 (ru) | 2007-11-27 | 2009-04-10 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ профилактики рецидива птеригиума |
EP2156834A1 (en) | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
EP2181991A1 (en) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
BRPI1008920A2 (pt) * | 2009-03-03 | 2015-08-25 | Alcon Res Ltd | Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho |
BRPI1015356A2 (pt) * | 2009-06-30 | 2016-05-10 | Allergan Inc | composições farmacêuticas oftalmológicas líquidas contendo derivados do ácido propiônico como conservante. |
JP2014518232A (ja) | 2011-06-28 | 2014-07-28 | バイエル・ヘルスケア・エルエルシー | ソラフェニブを含有する眼科用局所医薬組成物 |
EP2817031A4 (en) | 2012-02-22 | 2015-08-05 | Tufts College | COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT |
WO2013188283A1 (en) | 2012-06-12 | 2013-12-19 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sunitinib |
WO2013188268A1 (en) * | 2012-06-12 | 2013-12-19 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing pazopanib |
US20150164790A1 (en) | 2012-06-12 | 2015-06-18 | Bayer Healthcare Llc | Topical Ophthalmological Pharmaceutical Composition containing Axitinib |
US8747852B1 (en) | 2012-12-28 | 2014-06-10 | Randal Tanh Hoang Pham | Methods of treating pterygium |
WO2014158863A1 (en) | 2013-03-14 | 2014-10-02 | Massachusetts Eye And Ear Infirmary | Conjunctival diseases |
TWI700085B (zh) | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
-
2016
- 2016-05-13 TW TW108117515A patent/TWI700085B/zh active
- 2016-05-13 TW TW105114878A patent/TWI664965B/zh active
- 2016-05-27 AU AU2016283517A patent/AU2016283517B2/en active Active
- 2016-05-27 CN CN201680029483.5A patent/CN107708664B/zh active Active
- 2016-05-27 WO PCT/US2016/034822 patent/WO2016209555A1/en active Application Filing
- 2016-05-27 CA CA2989121A patent/CA2989121C/en active Active
- 2016-05-27 MX MX2017016655A patent/MX2017016655A/es unknown
- 2016-05-27 JP JP2017566347A patent/JP6680807B2/ja active Active
- 2016-05-27 KR KR1020207003834A patent/KR102096296B1/ko active IP Right Grant
- 2016-05-27 KR KR1020177034479A patent/KR20170140399A/ko active Application Filing
- 2016-05-27 EP EP16814997.9A patent/EP3310339A4/en active Pending
-
2017
- 2017-09-11 US US15/700,735 patent/US10154994B2/en active Active
-
2018
- 2018-04-27 US US15/964,235 patent/US11369600B2/en active Active
-
2022
- 2022-05-23 US US17/750,400 patent/US20220280506A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013166436A1 (en) * | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
WO2014074823A1 (en) * | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
JP2018521120A (ja) * | 2015-06-06 | 2018-08-02 | クラウドブレイク・セラピューティクス・エル・エル・シー | 翼状片を治療するための組成物及び方法 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF CONTROLLED RELEASE, vol. 200, JPN6018044160, 2015, pages 71 - 77, ISSN: 0004055195 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019534870A (ja) * | 2016-09-26 | 2019-12-05 | ルヤン (スーチョウ) バイオロジー サイエンス アンド テクノロジー カンパニー,リミテッド | 眼疾患の治療のための組成物ならびに使用および調製方法 |
JP7018939B2 (ja) | 2016-09-26 | 2022-02-14 | ルヤン (スーチョウ) バイオロジー サイエンス アンド テクノロジー カンパニー,リミテッド | 眼疾患の治療のための組成物ならびに使用および調製方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2989121C (en) | 2022-09-27 |
WO2016209555A1 (en) | 2016-12-29 |
TWI664965B (zh) | 2019-07-11 |
MX2017016655A (es) | 2018-05-15 |
KR20170140399A (ko) | 2017-12-20 |
US10154994B2 (en) | 2018-12-18 |
EP3310339A1 (en) | 2018-04-25 |
AU2016283517A1 (en) | 2017-12-14 |
CN107708664A (zh) | 2018-02-16 |
US20170368061A1 (en) | 2017-12-28 |
CA2989121A1 (en) | 2016-12-29 |
TWI700085B (zh) | 2020-08-01 |
TW201703770A (zh) | 2017-02-01 |
KR20200018714A (ko) | 2020-02-19 |
BR112017025757A2 (pt) | 2018-08-14 |
JP6680807B2 (ja) | 2020-04-15 |
US20220280506A1 (en) | 2022-09-08 |
US11369600B2 (en) | 2022-06-28 |
EP3310339A4 (en) | 2019-06-19 |
US20180243294A1 (en) | 2018-08-30 |
AU2016283517B2 (en) | 2019-01-03 |
KR102096296B1 (ko) | 2020-04-06 |
TW201936187A (zh) | 2019-09-16 |
CN107708664B (zh) | 2021-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220280506A1 (en) | Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof | |
Fangueiro et al. | Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo, in vitro and ex vivo studies | |
Hippalgaonkar et al. | Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation | |
Sahoo et al. | Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives | |
TWI752083B (zh) | 醫藥組合物 | |
JP2022009979A (ja) | 医薬組成物 | |
US8492334B2 (en) | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles | |
US20190070176A1 (en) | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug | |
Mehra et al. | Safety and toxicity of nanomaterials for ocular drug delivery applications | |
CN106061261B (zh) | 治疗化合物的结晶形式及其用途 | |
CN103142462A (zh) | 布林佐胺眼用制剂及其制备方法和用途 | |
JP6426195B2 (ja) | 治療用化合物の結晶形態及びその使用 | |
Fang et al. | Vesicular phospholipid gels as topical ocular delivery system for treatment of anterior uveitis | |
US20130316010A1 (en) | Polymeric microparticles | |
More et al. | Review on solid lipid nanoparticles for ophthalmic delivery | |
TWI707684B (zh) | 點眼用懸濁製劑 | |
BR112017025757B1 (pt) | Formulações oftálmicas de inibidores da tirosina quinase e suas composições farmacêuticas | |
Gandhi et al. | A review on current perspectives and recent advances in ocular drug delivery system | |
Campos et al. | Nanomedicines for Ocular NSAIDs: State-of-the-Art Update of the Safety on Drug Delivery | |
Acharya | Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents | |
Omerović et al. | Evaluation of Targeted Nanoparticles for Ocular Delivery | |
Patel | DESIGN AND DEVELOPMENT OF NOVEL DOSAGE FORMS FOR OPHTHALMIC DRUG DELIVERY SYSTEM | |
NGN et al. | LL GGGGGG GLG GLLL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171221 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190618 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190917 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200303 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200319 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6680807 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |